Volpara Receives FDA Clearance for Breast Density Algorithm
Software improves on breast density assessment algorithm with artificial intelligence.
Volpara Health announced Friday it has received 510(k) clearance from the U.S. Food & Drug Administration for the latest version of Volpara Imaging Software.
This version – VIS 3.2 – incorporates learnings from artificial intelligence to augment the robustness of the breast density assessment algorithm. In addition, this clearance approves VIS 3.2 for use on other mammography machines, including those from Giotto and Siemens.
The new version offers improved imaging processing security through the Open Virtual Appliance architecture, and it also makes it easier for Volpara to monitor, services, and update software, company officials said.
“These new innovations improve the overall security, scalability, robustness, and breadth of our breast health offering,” said Ralph Highnam, Ph.D., Volpara’s Group chief executive officer. “Our objective with each enhancement is the pursuit of our mission – to eliminate advanced-stage breast cancer and save more families from cancer.”
With this approval, Volpara marks its fifth clearance since launching Volpara Imaging Software in 2010. It is a key science algorithm that supports the Volpara Breast Health Platform, a product suite designed to improve early breast cancer detection through augmented mammography quality and workflow, volumetric breast density assessment, and personalized breast care.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
